Alkermes plc
ALKS
주식 순위
#2673
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
주가
$42.26
시가총액
$7.09B
변동 (1일)
2.51%
변동 (1년)
39.64%
국가
IE
거래 Alkermes plc (ALKS)
카테고리
Healthcare
Alkermes plc (ALKS)의 주식 분할 이력
Alkermes plc 주식 (심볼: ALKS)은 총 1회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 May 15, 2000에 발생했습니다.
May 15, 2000 이전에 매수한 ALKS 주식 1주는 현재 2주의 ALKS 주식에 해당합니다.
가장 최근의 분할은 May 15, 2000에 발생했습니다.
May 15, 2000 이전에 매수한 ALKS 주식 1주는 현재 2주의 ALKS 주식에 해당합니다.
주식 분할 목록
| 연도 | 주식 분할 | 배수 | 누적 배수 |
|---|---|---|---|
| 2000-05-15 | 2:1 | x2 | x2 |
유사 기업 또는 경쟁사의 주식 분할
| 회사 | 주식 분할 횟수 | 누적 배수 | 국가 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
